Landos Biopharma (Landos Biopharma) EBIT per Share : $-4.11 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Landos Biopharma EBIT per Share?

Landos Biopharma's EBIT per Share for the three months ended in Mar. 2024 was $-1.50. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.11.

During the past 3 years, the average EBIT per Share Growth Rate was 22.70% per year. During the past 5 years, the average EBIT per Share Growth Rate was -9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Landos Biopharma's EBIT per Share or its related term are showing as below:

LABP' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -44.3 Med: -35.2 Max: 22.7
Current: 22.7

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Landos Biopharma was 22.70% per year. The lowest was -44.30% per year. And the median was -35.20% per year.

LABP's 3-Year EBIT Growth Rate is ranked better than
73.64% of 1305 companies
in the Biotechnology industry
Industry Median: 3.6 vs LABP: 22.70

Landos Biopharma's EBIT for the three months ended in Mar. 2024 was $-9.30 Mil.

Landos Biopharma EBIT per Share Historical Data

The historical data trend for Landos Biopharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Landos Biopharma EBIT per Share Chart

Landos Biopharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-4.04

-7.83

-10.33

-10.08

-3.62

Landos Biopharma Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-1.00	-0.72	-0.84	-1.07	-1.50

Landos Biopharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Landos Biopharma's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-22.727	/	6.276
=	-3.62

Landos Biopharma's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-9.295	/	6.208
=	-1.50

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.11

Landos Biopharma (NAS:LABP) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Landos Biopharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Landos Biopharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Landos Biopharma (Landos Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Landos Biopharma Inc (NAS:LABP) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 11239, Blacksburg, VA, USA, 24060

Website

https://www.landosbiopharma.com

Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages.

Executives

Alka Batycky	director	C/O LANDOS BIOPHARMA, INC., P.O. BOX 11239, BLACKSBURG VA 24062
Perceptive Xontogeny Venture Fund Ii, Lp	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Roderick Wong	10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fabio Cataldi	officer: Chief Medical Officer	C/O LANDOS BIOPHARMA, INC., PO BOX 11239, BLACKSBURG VA 24062
Gregory Oakes	director, officer: Chief Executive Officer	760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
Patrick Truesdell	officer: Vice President and Controller	C/O LANDOS BIOPHARMA, INC., 1800 KRAFT DRIVE, SUITE 216, BLACKBURG VA 24060
Roger Adsett	director	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Josep Bassaganya-riera	director, 10 percent owner, officer: Chairman, President and CEO	1800 KRAFT DRIVE, SUITE 100, BLACKSBURG VA 24060
Patricia L Bitar	officer: Interim CFO	C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122
Perceptive Xontogeny Venture Fund, Lp	director	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Xontogeny, Llc	director	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Fred Callori	director	100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Joseph Edelman	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003